Your browser doesn't support javascript.
loading
Adult growth hormone deficiency: Optimizing transition of care from pediatric to adult services.
Yuen, Kevin C J; Alter, Craig A; Miller, Bradley S; Gannon, Anthony W; Tritos, Nicholas A; Samson, Susan L; Dobri, Georgiana; Kurtz, Kristine; Strobl, Frank; Kelepouris, Nicky.
Afiliação
  • Yuen KCJ; Barrow Pituitary Center, Barrow Neurological Institute, University of Arizona College of Medicine, Creighton School of Medicine, Phoenix, AZ, United States of America.
  • Alter CA; Perelman School of Medicine, University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.
  • Miller BS; Pediatric Endocrinology, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, United States of America.
  • Gannon AW; Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE, United States of America.
  • Tritos NA; Massachusetts General Hospital, Neuroendocrine Unit, Harvard Medical School, Boston, MA, United States of America.
  • Samson SL; Pituitary Center, Baylor St. Luke's Medical Center, Baylor College of Medicine, Houston, TX, United States of America.
  • Dobri G; Neurological Surgery and Endocrinology Departments, Weill Cornell Medicine, New York, NY, United States of America.
  • Kurtz K; Novo Nordisk Inc., Plainsboro, NJ, United States of America.
  • Strobl F; Novo Nordisk Inc., Plainsboro, NJ, United States of America.
  • Kelepouris N; Novo Nordisk Inc., Plainsboro, NJ, United States of America. Electronic address: nlkp@novonordisk.com.
Growth Horm IGF Res ; 56: 101375, 2021 02.
Article em En | MEDLINE | ID: mdl-33341524
ABSTRACT

OBJECTIVE:

Most patients with childhood-onset growth hormone deficiency (CO-GHD) receive treatment with exogenous growth hormone (GH) to facilitate the attainment of their full potential adult height. Recent evidence suggests that continuing GH administration during the transition period between the end of linear growth and full adult maturity is necessary for proper body composition and bone and muscle health, and may also have beneficial effects on metabolic parameters, bone mineral density, and quality of life. The timing of this transition period coincides with the transfer of care from a pediatric to an adult endocrinologist, creating the potential for a care gap as a consequence of losing the patient to follow-up.

DESIGN:

An advisory board comprising both pediatric and adult endocrinologists was assembled to address current clinical unmet needs and to collaborate on a structured transitional plan for optimal management of patients with CO-GHD. INSIGHTS/

CONCLUSION:

The advisors suggest collaborative, multidisciplinary approaches to ensure continuity of care; ongoing testing and monitoring of GHD status into adulthood; and a clearly structured protocol that includes practical guidance for clinicians to establish best practices for transitioning older adolescents with persistent CO-GHD to adult care.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pediatria / Hormônio do Crescimento Humano / Endocrinologia / Transição para Assistência do Adulto Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pediatria / Hormônio do Crescimento Humano / Endocrinologia / Transição para Assistência do Adulto Idioma: En Ano de publicação: 2021 Tipo de documento: Article